Clinical Trials Logo

Filter by:
NCT ID: NCT02975336 Terminated - Clinical trials for Systemic Lupus Erythematosus

A Phase II Study of M2951 in SLE

Start date: January 4, 2017
Phase: Phase 2
Study type: Interventional

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus (SLE).

NCT ID: NCT02973945 Recruiting - COPD Clinical Trials

High Flow Nasal Cannula and Aerobic Capacity Training

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare exercise capacity in Chronic Obstructive Pulmonary Disease (COPD) patients before and after an 8 week pulmonary rehabilitation program. Patients will be randomised in two groups, one arm will received oxygen through High Flow Nasal Cannula (HFNC) and the other group by The Venturi Mask (VM)

NCT ID: NCT02972840 Active, not recruiting - Clinical trials for Lymphoma, Mantle Cell

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Start date: April 5, 2017
Phase: Phase 3
Study type: Interventional

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

NCT ID: NCT02970461 Active, not recruiting - Chronic Disease Clinical Trials

Gamifying Patient's Personal Data Validation and Completion in a Personal Health Record

Start date: July 2016
Phase: N/A
Study type: Interventional

A randomized controlled trial design is used to test the efficacy of gamification elements to drive user behavior in a personal health record.

NCT ID: NCT02968004 Active, not recruiting - Clinical trials for Pediatric Growth Hormone Deficiency

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Start date: December 2016
Phase: Phase 3
Study type: Interventional

This will be an open-label, randomized, multicenter, efficacy and safety study of weekly MOD-4023 compared to daily Genotropin therapy in pre-pubertal children with growth hormone deficiency.

NCT ID: NCT02967692 Active, not recruiting - Melanoma Clinical Trials

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

COMBI-i
Start date: February 17, 2017
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma

NCT ID: NCT02964208 Completed - Stroke Clinical Trials

AMPLATZERâ„¢ LAA Occluder Post Approval Study (PAS)

Start date: December 8, 2016
Phase:
Study type: Observational

The aim of this multicenter, non-randomized observational post-approval is to compile real world outcome data on the use of an AMPLATZER LAA Occluder in subjects with non-valvular atrial fibrillation (NVAF). The AMPLATZER LAA Occluders is a transcatheter, self-expanding nitinol device intended for use in preventing thrombus embolization from the LAA.

NCT ID: NCT02963129 Not yet recruiting - Epistaxis Clinical Trials

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT

Start date: June 2017
Phase: Phase 3
Study type: Interventional

Compare the frequency of epistaxis and quality of life related to nasal bleeding in patients with HHT colonized with sataphylococo before and after being treated with mupirocin ointment.

NCT ID: NCT02962895 Completed - Clinical trials for Primary Sjogren Syndrome

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Start date: June 27, 2017
Phase: Phase 2
Study type: Interventional

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

NCT ID: NCT02962765 Completed - Hemophilia A Clinical Trials

Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ

Start date: January 2015
Phase:
Study type: Observational

Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients) and routine clinical practice. Besides aspects such as general product safety and efficacy, there will be a focus on immunogenicity, particularly on inhibitor development. The diagnosis of FVIII inhibitor will be based on clinical observations and confirmed by FVIII inhibitor testing in the laboratory.